Summary: Watch psychedelic researchers, including MAPS Founder Rick Doblin, Ph.D., speak about results from clinical studies into psychedelic-assisted psychotherapy during a presentation at the 2015 International Drug Policy Reform Conference.
Originally appearing here.
We are now in the midst of a psychedelic research renaissance. Clinical studies are under way at top medical schools and research institutes worldwide, and psychedelic therapy is beginning to be re-accepted by the medical community. Where are we at in the effort to make psychedelics legally available for medical and therapeutic purposes? And what does this mean for efforts to reduce the role of criminalization outside of medical or other clinical contexts?
Julie Holland, M.D., Psychopharmacologist, Psychiatrist, and Author, New York, NY
• Alex Belser, Ph.D., Administrative Director, New York University Psilocybin Cancer Anxiety and Spirituality Study, NYU Langone Medical Center, New York, NY
• Rick Doblin, Ph.D., Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS),
• Amanda Feilding, Executive Director, Beckley Foundation, Oxford, UK
• Albert Garcia, Ph.D., Faculty Member, Johns Hopkins University School of Medicine, Psychiatry and Behavioral Sciences, Baltimore, M.D.
• Ingmar Gorman, M.A., Doctoral Student, New School for Social Research, New York, NY
Thank you to the Drug Policy Alliance (http://drugpolicy.org) for hosting the International Drug Policy Reform Conference (http://reformconference.org).